Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists

Sarah Grimwood, Janusz J. Kulagowski, Ian M. Mawer, Michael Rowley, Paul D. Leeson, Alan C. Foster
{"title":"Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists","authors":"Sarah Grimwood,&nbsp;Janusz J. Kulagowski,&nbsp;Ian M. Mawer,&nbsp;Michael Rowley,&nbsp;Paul D. Leeson,&nbsp;Alan C. Foster","doi":"10.1016/0922-4106(95)00081-X","DOIUrl":null,"url":null,"abstract":"<div><p>Using radioligand binding studies, we have investigated the binding properties of four 4-hydroxy-2-quinolones, a novel series of selective antagonists for the glycine site on the <span><math><mtext>N-</mtext><mtext>methyl</mtext><mtext>-</mtext><mtext>d</mtext><mtext>-</mtext><mtext>aspartate</mtext></math></span> (NMDA) receptor. L-701,324, L-703,717, L-698,532 and L-695,902 inhibited [<sup>3</sup>H]L-689,560 (glycine site antagonist) binding to rat cortex/hippocampus P<sub>2</sub> membranes with IC<sub>50</sub> values of 1.97, 4.47, 209 and 6448 nM, respectively, whilst also inhibiting non-equilibrium [<sup>3</sup>H]dizocilpine binding to the NMDA receptor ion-channel. All four compounds partially inhibited <span>l</span>-[<sup>3</sup>H]glutamate (∼ 50% inhibition; agonist) binding and enhanced [<sup>3</sup>H]<em>cis</em>-4-phosphonomethyl-2-piperidine carboxylate ([<sup>3</sup>H]CGS-19755; 41–81% enhancement; ‘C-5’ antagonist) and [<sup>3</sup>H]3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonate ([<sup>3</sup>H]CPP; 28–66% enhancement; ‘C-7’ antagonist) binding to the glutamate recognition site of the NMDA receptor with EC<sub>50</sub> values similar to those observed for [<sup>3</sup>H]L-689,560 binding. These results provide further evidence for allosteric interactions between the glutamate and glycine recognition sites of the NMDA receptor complex, and as the 4-hydroxy-2-quinolones are ‘full’ antagonists at the glycine site, indicate that these interactions are not caused by the intrinsic activity of a compound.</p></div>","PeriodicalId":100502,"journal":{"name":"European Journal of Pharmacology: Molecular Pharmacology","volume":"290 3","pages":"Pages 221-226"},"PeriodicalIF":0.0000,"publicationDate":"1995-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0922-4106(95)00081-X","citationCount":"41","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmacology: Molecular Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/092241069500081X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

Abstract

Using radioligand binding studies, we have investigated the binding properties of four 4-hydroxy-2-quinolones, a novel series of selective antagonists for the glycine site on the N-methyl-d-aspartate (NMDA) receptor. L-701,324, L-703,717, L-698,532 and L-695,902 inhibited [3H]L-689,560 (glycine site antagonist) binding to rat cortex/hippocampus P2 membranes with IC50 values of 1.97, 4.47, 209 and 6448 nM, respectively, whilst also inhibiting non-equilibrium [3H]dizocilpine binding to the NMDA receptor ion-channel. All four compounds partially inhibited l-[3H]glutamate (∼ 50% inhibition; agonist) binding and enhanced [3H]cis-4-phosphonomethyl-2-piperidine carboxylate ([3H]CGS-19755; 41–81% enhancement; ‘C-5’ antagonist) and [3H]3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonate ([3H]CPP; 28–66% enhancement; ‘C-7’ antagonist) binding to the glutamate recognition site of the NMDA receptor with EC50 values similar to those observed for [3H]L-689,560 binding. These results provide further evidence for allosteric interactions between the glutamate and glycine recognition sites of the NMDA receptor complex, and as the 4-hydroxy-2-quinolones are ‘full’ antagonists at the glycine site, indicate that these interactions are not caused by the intrinsic activity of a compound.

四种新型甘氨酸位点拮抗剂对NMDA受体上谷氨酸位点的变构调节
利用放射性配体结合研究,我们研究了四种4-羟基-2-喹诺酮类药物的结合特性,这是n -甲基-d-天冬氨酸(NMDA)受体上甘氨酸位点的新型选择性拮抗剂。L-701,324、L-703,717、L-698,532和L-695,902抑制[3H]L-689,560(甘氨酸位点拮抗剂)与大鼠皮质/海马P2膜的结合,IC50值分别为1.97、4.47、209和6448 nM,同时抑制非平衡[3H]二唑西平与NMDA受体离子通道的结合。所有四种化合物都部分抑制l-[3H]谷氨酸(~ 50%抑制;[3H]顺式-4-磷酸亚甲基-2-哌啶羧酸酯([3H]CGS-19755;41 - 81%增强;' C-5 '拮抗剂)和[3H]3-(2-羧基哌嗪-4-基)-丙基-1-膦酸盐([3H]CPP;28 - 66%增强;' C-7 '拮抗剂)与NMDA受体谷氨酸识别位点结合,EC50值与[3H]L-689,560结合的EC50值相似。这些结果为NMDA受体复合物的谷氨酸和甘氨酸识别位点之间的变构相互作用提供了进一步的证据,并且由于4-羟基-2-喹诺酮类药物是甘氨酸位点的“完全”拮抗剂,表明这些相互作用不是由化合物的内在活性引起的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信